PolyActiva has announced the next important milestone of our transformational growth - the appointment of seasoned biopharmaceutical executive, Jerry St. Peter, as CEO and Board Director of PolyActiva, following the…

PolyActiva has recently secured $40 million (AUD) in Series C funding, led by the Australian National Reconstruction Fund (NRFC), and Australia's leading biotech investor, Brandon Capital. The funds will support…

PolyActiva has showcased their Phase 2 clinical data for their lead candidate PA5108 Ocular Implant in glaucoma patients. Patients received continuous therapy for intraocular pressure (IOP) for over 48 weeks,…

PolyActiva has recently been awarded a $1.5m CUREator Grant, which will be used to progress its second generation ocular implant as a treatment for patients with glaucoma, targeting sustained daily…

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients. The interim Phase 2a results demonstrate a sustained >20% reduction of IOP…

PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022

PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.